Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)

類似資料

• Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
  著者:: van der Aar, Ellen, 等
  出版事項: (2019)
• Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis
  著者:: Taneja, Amit, 等
  出版事項: (2019)
• Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
  著者:: Kreuter, Michael, 等
  出版事項: (2015)
• Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
  著者:: Santermans, Eva, 等
  出版事項: (2019)
• Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials
  著者:: Kreuter, Michael, 等
  出版事項: (2020)